
It was a case of three-in-one bits of good news for AstraZeneca and MSD, after the FDA boosted the newly …

In a shock move, MSD Chairman and Chief Executive Officer Kenneth Frazier (pictured) has announced that he is to resign …

Only last week it was revealed that the UK would administer all babes with the hepatitis B vaccine to reduce …

As part of Shire’s mega-merger with Baxalta, it suddenly had a massive manufacturing network that spanned 17 sites across seven …

It will be some time before the Mystic catastrophe hoo-ha dies down for AstraZeneca but it made a pre-emptive move …

Since the PD-1/PD-L1 immunotherapies have hit the market, they have revolutionised cancer care for many patients yet, with the science …

MSD, known as Merck in North America, has been granted approval for its biosimilar of Sanofi’s diabetes treatment, Lantus. Potentially, …

Following on from the news last month that enrolment for Keytruda being used alongside Celgene’s Imnovid and Revlimid would have …

Following the recent and heavily-publicised ransomware attack which hit the NHS in the UK and almost 100 other countries, the …

There were fears in Ireland that President Trump’s strong words to bring manufacturing back to the US would hurt the …

In a historic first, MSD (known as Merck in North America) has received approval for its immunotherapy treatment Keytruda in …

MSD is facing legal trouble after the Competition and Marketing Authority (CMA) alleged that the pharmaceutical firm had engaged in …

New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …

MSD, otherwise known as Merck in North America, continues to score indication successes with Keytruda, this time in Hodgkin lymphoma. …

The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, …